Andrew K Dilger

Title: The Innovative Contributions of Andrew K. Dilger

Introduction

Andrew K. Dilger is a notable inventor based in Ewing, NJ (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 17 patents to his name, Dilger has made remarkable advancements in the development of therapeutic agents.

Latest Patents

Among his latest patents, Dilger has developed compounds known as Pyrimidinones as factor XIa inhibitors. This invention provides compounds of Formula (I) or their stereoisomers, tautomers, or pharmaceutically acceptable salts. These compounds serve as selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. The invention also encompasses pharmaceutical compositions that include these compounds and methods for treating thromboembolic and inflammatory disorders. Another significant patent involves antibodies and antigen binding peptides for factor XIa inhibitors. This invention presents novel antigen binding peptides, such as antibodies or antibody fragments, that specifically bind to selective FXIa inhibitors and dual inhibitors of FXIa and plasma kallikrein. Furthermore, it relates to methods for reducing the antithrombotic effect of FXIa inhibitors by administering a pharmaceutically effective dose of the provided antigen binding peptides.

Career Highlights

Dilger has had a distinguished career, working with prominent companies such as Bristol-Myers Squibb Company and Bristol-Myers Squibb. His work in these organizations has contributed to the advancement of pharmaceutical research and development.

Collaborations

Throughout his career, Dilger has collaborated with notable colleagues, including Kumar Balashanmuga Pabbisetty and William R. Ewing. These collaborations have fostered innovation and the sharing of ideas in the field of pharmaceuticals.

Conclusion

Andrew K. Dilger's contributions to the pharmaceutical industry through his patents and collaborations highlight his role as a leading inventor. His work continues to impact the development of important therapeutic agents.